Scancell reports strong results from Immunobody trial
By Josh White
Date: Friday 07 Nov 2025
(Sharecast News) - Scancell Holdings reported strong phase two results for its Immunobody iSCIB1+ cancer immunotherapy on Friday, showing significant improvements in progression-free survival for patients with late-stage melanoma.
The AIM-traded firm said the data, presented in an oral session at the Society for Immunotherapy of Cancer's (SITC) 40th Anniversary Annual Meeting in Maryland, demonstrated that iSCIB1+ could set a new benchmark in efficacy, durability, immune response and safety for melanoma treatment.
It said the ongoing 'Scope' trial found that iSCIB1+ achieved a progression-free survival rate of 78% at 11 months in patients with the target human leukocyte antigen (HLA) type, compared with a historic 12-month rate of 46% for the current standard doublet checkpoint therapy of ipilimumab and nivolumab.
Combined data across patient cohorts also showed a 22-month progression-free survival rate of 69%, reinforcing the therapy's potential to outperform existing treatments.
"The data from SCOPE so far indicate that iSCIB1+ has groundbreaking potential to deliver meaningful clinical benefits to patients," said Dr Nermeen Varawalla, chief medical officer of Scancell.
"It has been shown to enhance response rates, disease control, progression-free survival and immune activation, combined with a robust safety profile that allows integration with standard of care without added toxicity.
"This positions iSCIB1+ as a transformative option for patients with metastatic melanoma and opens possibilities for earlier-stage, resectable disease in neoadjuvant or adjuvant settings, and we are looking forward to moving this exciting Immunobody into randomised studies, on the path to registration, in 2026."
Scancell said more than 100 patients had now been treated across the Scope trial, with the therapy continuing to show a favourable safety profile.
The company said it planned to accelerate the development of iSCIB1+, which it expected would expand its addressable population to around 80% of patients with late-stage melanoma and benefit from a longer patent life.
Following the latest data, Scancell said it had started regulatory and partnering discussions and expected to initiate randomised registration studies for iSCIB1+ in 2026.
At 1224 GMT, shares in Scancell Holdings were up 4.2% at 10.26p.
Reporting by Josh White for Sharecast.com.
Email this article to a friend
or share it with one of these popular networks:
You are here: news
10 Lower Thames St,
London EC3R 6EN